Related Experiment Video
Updated: Apr 7, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.8K
Current and future molecular diagnostics in non-small-cell lung cancer
Chun Man Li1, Wing Ying Chu, Di Lun Wong
1Department of Health Technology and Informatics, Faculty of Health and Social Sciences, Hong Kong Polytechnic University, Hong Kong Special Administrative Region, Hong Kong, China.
Expert Review of Molecular Diagnostics
|July 9, 2015
Summary
Molecular biomarkers are revolutionizing lung cancer care. Advances in gene alterations, epigenetic changes, and microRNA offer new diagnostic and personalized treatment strategies for non-small-cell lung cancer.
Area of Science:
- Oncology and Molecular Biology
- Cancer Genomics
- Biomarker Discovery
Background:
- Molecular investigations are transforming lung cancer diagnosis and treatment.
- Gene alterations drive cancer initiation and progression, offering therapeutic targets.
- Personalized medicine relies on understanding molecular changes for targeted therapies.
Purpose of the Study:
- To review current and emerging molecular biomarkers for non-small-cell lung cancer (NSCLC).
- To discuss advancements in molecular diagnostics for lung cancer.
- To provide recommendations for future molecular diagnostic services.
Main Methods:
- Literature review of molecular biomarkers in NSCLC.
- Analysis of gene alterations, epigenetic aberrations, and microRNA dysregulation.
- Evaluation of diagnostic and therapeutic implications of biomarkers.
Main Results:
- Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement are key predictive biomarkers for tyrosine kinase inhibitor (TKI) efficacy.
- Epigenetic aberrations and microRNA dysregulation show promise for early detection and monitoring.
- Standardization and validation of molecular assays are crucial for reliable results.
Conclusions:
- Molecular biomarkers are essential for personalized targeted therapy in lung cancer.
- Emerging biomarkers offer new avenues for early detection and treatment monitoring.
- Continued development and standardization of molecular diagnostic services are vital for improving patient outcomes.
